Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ultragenyx Pharmaceutical

35.13
-0.2400-0.68%
Post-market: 35.130.00000.00%16:05 EDT
Volume:631.79K
Turnover:22.11M
Market Cap:3.25B
PE:-5.59
High:35.47
Open:34.35
Low:34.29
Close:35.37
Loading ...

U.S. RESEARCH ROUNDUP- Apple, Murphy USA, UnitedHealth

Reuters
·
21 Jan

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
18 Jan

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
18 Jan

Why Ultragenyx Pharmaceutical (RARE) Is the Biotech Stock with the Biggest Upside Potential

Insider Monkey
·
18 Jan

Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside

Benzinga
·
16 Jan

Ultragenyx Pharma Price Target Maintained With a $48.00/Share by Wedbush

Dow Jones
·
13 Jan

Ultragenyx Pharmaceutical (RARE) Receives a Hold from Wedbush

TIPRANKS
·
13 Jan

Evercore ISI Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
13 Jan

U.S. RESEARCH ROUNDUP- Constellation Brands, Merck, WD-40

Reuters
·
13 Jan

Ultragenyx Pharmaceutical Inc : Piper Sandler Raises Target Price to $140 From $135

THOMSON REUTERS
·
13 Jan

Strong Buy Recommendation for Ultragenyx Pharmaceutical Based on Robust Performance and Promising Clinical Pipeline

TIPRANKS
·
13 Jan

Ultragenyx Pharmaceutical: Strong Revenue Forecasts and Pipeline Advancements Justify Buy Rating

TIPRANKS
·
13 Jan

BRIEF-Ultragenyx Pharmaceutical Inc Says 2025 Revenue Guidance $640 Mln-$670 Mln

Reuters
·
13 Jan

Ultragenyx Pharmaceutical Inc - 2025 Revenue Guidance $640M-$670M

THOMSON REUTERS
·
13 Jan

Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones

GlobeNewswire
·
13 Jan

RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use

Zacks
·
07 Jan

Bank of America Securities Remains a Buy on Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
07 Jan

BRIEF-Ultragenyx Pharma Says EC Expands Evkeeza Approval For HoFH To Children As Young As 6 Months

Reuters
·
06 Jan

Ultragenyx Pharmaceutical: European Commission Extends Approval of Evkeeza to Children as Young as 6-Months Old With Hofh

THOMSON REUTERS
·
06 Jan

European Commission (EC) Extends the Approval of Evkeeza® (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH)

GlobeNewswire
·
06 Jan